Jeffrey C. Goh - Concepedia

Author

Jeffrey C. Goh

Royal Brisbane and Women's Hospital ORCID

Also Known As

Andrew Weickhardt, J C Goh, J Goh, J. C. Goh, J. Goh, J.C. Goh, J.C.H. Goh, Jeff Goh, Jeffrey C Goh, Jeffrey C. Goh

129

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

Royal Brisbane and Women's Hospital Memorial Sloan Kettering Cancer Center The University of Queensland Vall d'Hebron Institute of Oncology University College London

About

Jeffrey C. Goh is an author at Royal Brisbane and Women's Hospital specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	27	5K
2	Health Sciences	10	10	442
3	Immunology	4	4	64
4	Diagnostic Sciences	3	3	110
5	Emergency Medicine	1	1	41

Jeffrey C. Goh

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, New England Journal of Medicine	2021	1.7K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Toni K. Choueiri, Thomas Powles, Mauricio Burotto, New England Journal of Medicine	2021	1.6K
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Journal of Clinical Oncology	2019	679
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial Robert J. Motzer, Paul Russo, Viktor Grünwald, The Lancet UrologySurgical OncologyGenitourinary CancerMedicineSurgery	2023	159
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, The Lancet Oncology Pembrolizumab Versus SunitinibUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2023	149
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Robert J. Motzer, Camillo Porta, Masatoshi Eto, Journal of Clinical Oncology	2024	126
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial Louise Emmett, Shalini Subramaniam, Megan Crumbaker, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyClinical Trials	2024	123
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial Jonathan A. Ledermann, Amit M. Oza, Domenica Lorusso, The Lancet Oncology Post-progression OutcomesMedicineMetronomic TherapyRecurrent Ovarian CarcinomaGynecology	2020	122

Page 1